2017
Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.
Goldman J, Antonia S, Gettinger S, Borghaei H, Brahmer J, Ready N, Gerber D, Chow L, Juergens R, Shepherd F, Laurie S, Geese W, Li A, Li X, Hellmann M. Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012. Journal Of Clinical Oncology 2017, 35: 9093-9093. DOI: 10.1200/jco.2017.35.15_suppl.9093.Peer-Reviewed Original ResearchPD-L1 expressionComplete responsePD-L1Long-term OS benefitPD-L1 tumor expressionStage IIIB/IVTumor PD-L1 expressionChemotherapy-naive NSCLCECOG PS 0Experienced grade 3IIIB/IVManageable safety profileFirst-line treatmentPhase 1 studyLong-term survivorsLong-term outcomesMultiple tumor typesExploratory endpointsOS benefitAdvanced NSCLCPrimary endpointSecondary endpointsPS 0Unacceptable toxicityConsent withdrawal
2013
Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.
Powderly J, Koeppen H, Hodi F, Sosman J, Gettinger S, Desai R, Tabernero J, Soria J, Hamid O, Fine G, Xiao Y, Mokatrin A, Wu J, Anderson M, Irving B, Chen D, Kowanetz M. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. Journal Of Clinical Oncology 2013, 31: 3001-3001. DOI: 10.1200/jco.2013.31.15_suppl.3001.Peer-Reviewed Original ResearchPD-L1 expressionPD-L1Blood-based biomarkersPD-1T cellsPD-L1 tumor expressionTumor samplesT-cell gene signaturePD-L1 blockadeT cell infiltrationMetastatic solid tumorsPD-L1 upregulationT cell reactivationT cell subsetsImmune cell subsetsTumor immune microenvironmentPretreatment tumor samplesAvailable tumor tissueHuman monoclonal antibodyActivated T cellsT cell activationTumor CD8Expansion cohortAntitumor immunityBiopsy cohort